Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 1/2 1

Status

Recruiting 43Completed 23Terminated 16Unknown 8Active not recruiting 8Withdrawn 4Not yet recruiting 4Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 8Pancreatic Neoplasms 4Myelodysplastic Syndromes 3Melanoma 3Leukemia, Myeloid, Acute 3Leukemia 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Stomach Neoplasms 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lung Neoplasms 2Colorectal Neoplasms 2Vulvar Neoplasms 1Vaginitis 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Solid Tumors 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rectal Neoplasms 1Primary Myelofibrosis 1

Interventions

Nivolumab 1E-3810 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Suspended × Endometrial Neoplasms × Clear all
NCT04042116 2022-12-20

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

Clovis Oncology, Inc.

Phase 1/2 Suspended
227 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡